Mouse prostate reconstitution: An in vivo transgenic gland model system

Urologic Oncology

Volumn 2, Issue 4, 1996, Pages 117-119

  Thompson, Timothy C ^a  

^a Fannin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343155330     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)82843-8     Document Type: Article

References (39)

1. Grobstein C. Inductive interaction in the development of the mouse metanephros. J Exp Zool 1955:130:319-39.
2. McLoughlin CB. The importance of mesenchymal factors in differentiation of chick epidermis. II. Modification of epidermal differentiation by contact with different types of mesenchyme. J Emb Expl Morph 1961;9:385-409.
3. Moscona AA. Environmental factors in experimental studies on histogenesis. Colloque sur la culture Organotypique 1961;101:156-68.
4. Golosow N, Grobstein C. Epithelio-mesenchymal interactions in pancreatic morphogenesis. Develop Biol 1962;4:242-55.
5. Sigot M. Sur le role mesenchyme dans la différenciation des glandes du proventricule chez l'embryon de poulet. Compt Rend Acad Sci 1962;254:2349-441.
6. Rawles ME. Tissue interactions in scale and feather development as studied in dermal-epidermal recombinations. J Emb Exptl Morph 1963;11:765-89.
7. Kollar EJ. An in vitro study of hair and vibrissae development in embryonic mouse skin. J Invest Dermatol 1966;46:254-62.
8. Wessells NK. Differentiation of epidermis and epidermal derivatives. New Engl J Med 1967;277:21-33.
9. Dameron F. Etude expérimentale de l'orgenogenese du Poumon: Nature et spécificité des interactions epitheliomesenchymateuses. J Emb Exptl Morph 1968:20:151-67.
10. Wolff E. Specific interactions between tissues during organogenesis. Current Topics in Develop Biol 1968;3:65-94.
11. Kratochwil K. Organ specificity in mesenchymal induction demonstrated in the embryonic development of the mammary gland of the mouse. Develop Biol 1969;20:46-71.
12. Kollar RJ. The induction of hair follicles by embryonic dermal papillae. J Invest Dermatol 1970;55:374-8.
13. Cunha GR. Epithelio-mesenchymal interactions in primordial gland structures which become responsive to androgenic stimulation. Anat Rec 1972;172:179-96.
14. Cunha GR, Fujii H, Neubauer BL, Shannon JM, Sawyer LM, Reese BA. Epithelial-mesenchymal interactions in prostatic development. I. Morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 1983;96:1662-70.
15. Neubauer BL, Chung LWK, McCormick K, Taguchi 0, Thompson TC, Cunha GR. Epithelial-mesenchymal interactions in prostatic development. II. Biochemical observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 1983;96:1671-6.
16. Cunha GR, Chung LWK, Shannon JM, Taguchi O, Fujii H. Hormone-induced morphogenesis and growth: Role of mesenchymal-epithelial interactions. Recent Prog Horm Res 1983;39:559-98.
17. Thompson TC, Southgate J, Kitchner G, Land H. Multi-stage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56:917-30.
18. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992;356:215-21.
19. Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA, Bradley A, Kadmon D, Yang G. Loss of p53 function leads to metastasis in ras + nyc-initiated mouse prostate cancer. Oncogene 1995;10:869-79.
20. Varmus HE. Retroviruses. Science 1988;240:1427-35.
21. Anwar K, Nakakuki K, Shimishi T, et al. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 1992;52:5991-6.
22. Konishi N, Enomoto T, Buzard G, et al. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 1992;69:2293-9.
23. Gumerlock PH, Poonamallee UR, Meyers FJ, deVere White RW. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 1991 ;51:1632-7.
24. Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. Cancer Res 1990;50:6830-2.
25. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of the c-myc protooncogene in high grade human prostate cancers. The Prostate 1987;ll:327-37.
26. Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG, Matusik RJ. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 1986;46:1535-8.
27. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV. Mutation of the MX11 gene in prostate cancer. Nature Genetics 1995;9:249-55.
28. Thompson TC, Timme TL, Egawa S, Park SH, Kadmon D, Yoshida K. Genetic predisposition and mesenchymal-epithelial interactions in ras + myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog 1993;7:165-79.
29. Thompson TC. Growth factors and oncogenes in prostate cancer. Cancer Cells 1990;2:345-54.
30. Merz VW, Miller GJ, Krebs TK, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC. Elevated transforming growth factor-bl and b3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: Evidence for a paracrine role during progression. Mol Endocrinol 1991;5:503-13.
31. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor-bl with prostate cancer: An immunohistochemical study. Hum Pathol 1993;24:4-9.
32. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC. Transforming growth factor-bl: Comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 1995;5:628-35.
33. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-73.
34. Navone NM, Troncosco P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Inst 1993;85:1657-69.
35. Eastham JA, Stapleton AMF, Gousse AE, Timme TL, et al. Association of p53 mutations with metastatic prostate cancer. Clin Can Res 1995:1:1111-8.
36. Yang G, Stapleton AMF, Wheeler TM, Truong LD, Timme TL, Scardino PT, Thompson TC. Clustered p53 immunostaining: A novel pattern associated with prostate cancer progression. Clin Cancer Res 1996;2:399-401.
37. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras + myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 1993:53:4461-3.
38. Baley PA, Yoshida K, Qian W, Sehgal I, Thompson TC. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 1995;52:403-13.
39. Eastham JA, Chen S-H, Sehgal 1, Yang G, Timme TL, Hall SJ, Woo SLC, Thompson TC. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse prostatic cancer models. Human Gene Therapy 1996;7:515-23.